Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38

Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.